SOTIO® Biotech is developing the next generation of potent immunotherapies for patients with cancer.

 

The robust SOTIO Biotech clinical pipeline includes a differentiated superagonist of the attractive immuno-oncology target IL-15, a proprietary technology designed to improve on the efficacy of CAR T therapies, a platform to streamline and enhance personalized cell therapies and a new generation of potent and stable antibody-drug conjugates.

 

SOTIO® Biotech is focused on advancing safer
and more effective immunotherapies
through clinical development.

 

Join Our Team

SOTIO is shaping the future of cancer immunotherapies by translating compelling science into patient benefit. We are looking for talented, motivated, dynamic employees to join our international ...

Business Development

SOTIO aims to become a diverse oncology company that develops early stage candidates into marketed immunotherapy products. We seek to add to our portfolio projects that are at advanced preclinical or clinical stages.

NEWS

SOTIO Presents Preclinical Data from BOXR CAR-T Program and Trial Design of Phase 2 AURELIO-04 Study at SITC Annual Meeting

Findings on the mechanism of action from the BOXR CAR-T platform indicate improved metabolic function and preservation of early memory subsets of T cells  SOTIO anticipates initiating first-in ...

SOTIO Programs

SOT101 (formerly SO-C101)

SOT101 (formerly SO-C101) is an IL-15 superagonist that has been precisely designed and optimized for its use as a potent immunotherapy. It is currently being studied in an ongoing Phase 1/1b study …

BOXR

SOTIO’s BOXR cell therapy platform is designed to improve the functionality of engineered T cells by identifying novel “bolt-on” transgenes that can be co-expressed with tumor-targeting receptors to overcome resistance and improve the function of T cells in the solid tumor microenvironment. 

Antibody-Drug Conjugates

SOTIO’s proprietary antibody-drug conjugate (ADC) platform yields potent and highly stable ADCs with a wide therapeutic window for the treatment of cancer …

Contacts

Boston
Boston
SOTIO Biotech Inc.
180 Canal St,
Suite 300
Boston, MA 02114
USA
CONTACT
Prague
Prague
SOTIO Biotech a.s.
Jankovcova 1518/2
170 00 Prague 7
Czech Republic
CONTACT
Basel
Basel
SOTIO Biotech AG
Lichtstrasse 35 - WSJ-210
4056 Basel
Switzerland
CONTACT
Amsterdam
Amsterdam
SOTIO Biotech B.V.
Strawinskylaan 933
1077XX Amsterdam
Netherlands
CONTACT